BioCentury | Nov 8, 2019
Emerging Company Profile

Arkuda emerges from Atlas with genetic dementia program

Atlas-founded Arkuda is developing compounds for frontotemporal dementia due to genetic lysosomal deficits that could be applied to other neurodegenerative diseases linked to lysosomal dysfunction. Arkuda Therapeutics Inc. debuted Thursday with a $44 million series...
BC Extra | Jul 20, 2019
Clinical News

July 19 Clinical Quick Takes: Polyphor closes Phase III murepavadin trials; plus Takeda and Alector

Polyphor ends PRISM trials  The Swiss immuno-oncology company Polyphor AG (SIX:POLN) closed the Phase III PRISM MDR and PRISM UDR trials of its IV formulation of murepavadin for hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) after...
BC Innovations | Mar 24, 2011
Cover Story

New front against TNF

New York University School of Medicine researchers have designed a molecule based on the growth factor progranulin that could help treat rheumatoid arthritis and other autoimmune diseases. 1 The team has formed a company, ATreaon...
BC Innovations | Feb 10, 2011
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Granulin (GRN) Mouse and human sample studies suggest that inhibiting GRN could help treat cancer. In mice implanted with poorly tumorigenic human cells, GRN...
Items per page:
1 - 4 of 4